A few successful examples document promise of such approaches: RT plus androgen deprivation to treat locally advanced prostate cancer or RT plus cetuximab, an inhibitory antibody against the epidermal growth factor receptor (EGFR), to treat head and neck cancer patients not tolerating concurrent cisplatin chemotherapy (CT) [26,27,28,29] and more recently, immunotherapy [30,31]. The gene discussed is EGFR; the disease is prostate carcinoma.